A detailed history of Susquehanna International Group, LLP transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 154,834 shares of INMB stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
154,834
Previous 43,836 253.21%
Holding current value
$1.25 Million
Previous $493,000 268.97%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$10.53 - $14.01 $1.17 Million - $1.56 Million
110,998 Added 253.21%
154,834 $1.82 Million
Q4 2023

Feb 14, 2024

BUY
$6.6 - $11.52 $79,167 - $138,182
11,995 Added 37.67%
43,836 $493,000
Q3 2023

Nov 14, 2023

SELL
$6.61 - $10.9 $60,613 - $99,953
-9,170 Reduced 22.36%
31,841 $215,000
Q2 2023

Aug 11, 2023

SELL
$6.5 - $10.09 $192,569 - $298,926
-29,626 Reduced 41.94%
41,011 $372,000
Q1 2023

May 16, 2023

BUY
$6.01 - $10.18 $338,621 - $573,571
56,343 Added 394.17%
70,637 $456,000
Q4 2022

Feb 14, 2023

SELL
$6.31 - $7.96 $59,812 - $75,452
-9,479 Reduced 39.87%
14,294 $90,000
Q3 2022

Nov 14, 2022

BUY
$6.91 - $10.44 $164,271 - $248,190
23,773 New
23,773 $147,000
Q1 2022

May 16, 2022

SELL
$6.42 - $11.39 $247,401 - $438,925
-38,536 Reduced 42.54%
52,042 $438,000
Q4 2021

Feb 14, 2022

BUY
$9.97 - $20.38 $80,248 - $164,038
8,049 Added 9.75%
90,578 $924,000
Q3 2021

Nov 15, 2021

BUY
$14.13 - $27.85 $96,295 - $189,797
6,815 Added 9.0%
82,529 $1.6 Million
Q2 2021

Aug 11, 2021

BUY
$9.29 - $19.33 $396,144 - $824,269
42,642 Added 128.94%
75,714 $1.33 Million
Q1 2021

May 17, 2021

BUY
$11.61 - $26.85 $383,965 - $887,983
33,072 New
33,072 $393,000
Q2 2020

Aug 14, 2020

SELL
$3.1 - $6.09 $35,473 - $69,687
-11,443 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$2.21 - $6.15 $25,289 - $70,374
11,443 New
11,443 $38,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $145M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.